Ascendis Pharma Presents Long-Term Data on Achondroplasia Treatments at ICCBH 2026
Event summary
- Ascendis Pharma will present Week 104 data from the ApproaCH Trial of TransCon CNP (navepegritide) at ICCBH 2026, showing improvements in lower-extremity alignment.
- Late-breaking poster reveals Week 52 radiographic and anthropometric data from the COACH Trial combining TransCon CNP and TransCon hGH (lonapegsomatropin).
- TransCon CNP was approved by the FDA as YUVIWEL® in February 2026 and is under review by the European Medicines Agency.
- ICCBH 2026 conference runs June 27-30 in Montreal, featuring Ascendis' oral presentation on June 29.
The big picture
Ascendis Pharma's presentation of long-term data for its achondroplasia treatments comes as the company seeks to solidify its position in the rare disease space. The approval of TransCon CNP (YUVIWEL®) by the FDA and its pending review in Europe represent key milestones in addressing a condition with significant unmet medical needs. The strategic focus on combination therapies could expand treatment options for patients while differentiating Ascendis from competitors in this niche market.
What we're watching
- Regulatory Progress
- Whether the European Medicines Agency will approve TransCon CNP as a monotherapy for achondroplasia, following its February 2026 FDA approval.
- Clinical Efficacy
- How sustained improvements in lower-extremity alignment and skeletal dysplasia manifestations from the combination therapy will impact long-term patient outcomes.
- Market Expansion
- The pace at which Ascendis can expand its rare disease portfolio beyond achondroplasia into other high-unmet-need indications.